Methods for determining prognosis of colorectal cancer
Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2α, CAIX, PDGFRβ, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.
1. A method of labeling a tissue sample array comprising:
obtaining a tissue sample array having a plurality of tissue samples from a subject,
contacting a plurality of the tissue samples with an antibody that specifically binds vimentin,
contacting a plurality of the tissue samples with an antibody that specifically binds cytokeratin and a second antibody that specifically binds CD31,
contacting a plurality of the tissue samples with an antibody that specifically binds vimentin and a second antibody that specifically binds CD31,
contacting a plurality of the tissue samples with an antibody that specifically binds cytokeratin,
wherein,
at least one tissue sample contacted with an antibody that specifically binds vimentin is also contacted with an antibody that specifically binds TEM-1,
at least one tissue sample contacted with an antibody that specifically binds cytokeratin and a second antibody that specifically binds CD31 is also contacted with an antibody that specifically binds TEM-1,
at least one tissue sample contacted with an antibody that specifically binds vimentin and a second antibody that specifically binds CD31 is also contacted with an antibody that specifically binds HIF2α,
at least one tissue sample contacted with an antibody that specifically binds cytokeratin is also contacted with an antibody that specifically binds collagen IV, and
at least one tissue sample contacted with an antibody that specifically binds vimentin is also contacted with an antibody that specifically binds fibronectin-1,
wherein the tissue sample array is then assessed for degree of labeling.
2. A method of labeling a tissue sample array comprising:
obtaining a tissue sample array having a plurality of tissue samples from a subject,
contacting a plurality of the tissue samples with an antibody that specifically binds vimentin, and
contacting a plurality of the tissue samples with an antibody that specifically binds cytokeratin,
wherein,
at least one tissue sample contacted with an antibody that specifically binds vimentin is also contacted with an antibody that specifically binds TEM-1,
at least one tissue sample contacted with an antibody that specifically binds cytokeratin is also contacted with an antibody that specifically binds collagen IV, and
at least one tissue sample contacted with an antibody that specifically binds vimentin is also contacted with an antibody that specifically binds fibronectin-1,
wherein the tissue sample array is then assessed for degree of labeling.